Clinical trials
Lung Neoplasms trials in Czechia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 4 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 12 |
| Active, not recruiting | 4 |
| Terminated | 4 |
| Unknown status | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Bristol-Myers Squibb | 5 |
| Amgen | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| Gustave Roussy, Cancer Campus, Grand Paris | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Novartis Pharmaceuticals | 2 |
| Pfizer | 2 |
| Revolution Medicines, Inc. | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Neoplasms | 48 |
| Carcinoma, Non-Small-Cell Lung | 31 |
| Neoplasms | 7 |
| Carcinoma | 6 |
| Lung Diseases | 6 |
| Neoplasm Metastasis | 4 |
| Small Cell Lung Carcinoma | 4 |
| Bronchial Neoplasms | 3 |
| Neoplasms by Site | 3 |
| Ovarian Neoplasms | 3 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.